RP-HPLC stability method development & validation for anti-HIV drugs cabotegravir & rilpivirine in I.M. injection and in human plasma

Yogi Pandya; Samixa Patel

doi:10.53730/ijhs.v6nS1.7056

Authors

Yogi Pandya
yogipandyapharm@gmail.com
Research Scholar, School Of Pharmaceutical Sciences, Atmiya University, Rajkot, Gujarat, India – 360005
Samixa Patel Associate Professor, School Of Pharmaceutical Sciences, Atmiya University, Rajkot, Gujarat, India - 360005

Keywords:

RP-HPLC, Stability, Antiviral, HIV, Cabotegravir, Rilpivirine, I.M. Injection, Human Plasma

Abstract

In Pharmaceutical & Medical Health Sciences there are necessities for development of analysis methods for medicines in various dosage forms. Currently the use of RP-HPLC is primarily applied for testing of medicines in various dosage forms, and to study bio analysis in human plasma matrix. The present method is developed for analysis of anti HIV drugs cabotegravir CAB and rilpivirine RILP in pure api & Intramuscular Injection dosage forms, and also in human plasma. The HPLC method is optimized for analysis of these two drugs in combined forms for swift analysis with very less amount of drugs utilized for testing purposes. The concentration range used for the linearity studies is 2.5 to 15µg/ml for CAB cabotegravir & for Rilpivirine RILP it is 3.75 to 22.5µg/ml. Wavelength selected for estimation is 242.5nm and column used was Kinetex C-18 column (250mm x 4.6mm, 5 µm id). The Retention-time obtained were 2.14min for CAB & 3.12min for RILP. The R² was found to be 0.999 for both drugs. The method is applied for analysis of drugs in i.m. injections, individually & in combined forms.

Downloads

Download data is not yet available.

References

De Clercq, E. (2012). Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era. Biochemical Pharmacology, 84(3), 241–248. https://doi.org/10.1016/j.bcp.2012.03.024

Durham, S. H., & Chahine, E. B. (2021). Cabotegravir-Rilpivirine: The First Complete Long-Acting Injectable Regimen for the Treatment of HIV-1 Infection. Annals of Pharmacotherapy, 55(11), 1397–1409. https://doi.org/10.1177/1060028021995586

Fernandez, C., & van Halsema, C. L. (2019). Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential. HIV/AIDS - Research and Palliative Care, Volume 11, 179–192. https://doi.org/10.2147/HIV.S184642

Guideline, I. C. H. (2005). Q2 (R1): validation of analytical procedure: text and methodology. ICH, London.

Guideline, I. H. T. (2003). Stability testing of new drug substances and products. Q1A (R2), Current Step, 4, 1–24.

Howe, Z. W., Norman, S., Lueken, A. F., Huesgen, E., Farmer, E. K., Jarrell, K., Mathis, J. E., Bonham, K. W., & Hahn, J. (2021). Therapeutic review of cabotegravir/rilpivirine long‐acting antiretroviral injectable and implementation considerations at an HIV specialty clinic. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 41(8), 686–699. https://doi.org/10.1002/phar.2605

ICH, Q. (R1). (2005). Proceedings of International Conference of Harmonization.

Kovač, L., Časar, Z., Trdan Lušin, T., & Roškar, R. (2022). Development of an Analytical Method for Determination of Related Substances and Degradation Products of Cabotegravir Using Analytical Quality by Design Principles. ACS Omega, 7(10), 8896–8905. https://doi.org/10.1021/acsomega.1c07260

Margolis, D. A., Brinson, C. C., Smith, G. H. R., de Vente, J., Hagins, D. P., Eron, J. J., Griffith, S. K., Clair, M. H. S., Stevens, M. C., Williams, P. E., Ford, S. L., Stancil, B. S., Bomar, M. M., Hudson, K. J., Smith, K. Y., & Spreen, W. R. (2015). Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. The Lancet Infectious Diseases, 15(10), 1145–1155. https://doi.org/10.1016/S1473-3099(15)00152-8

McPherson, T. D., Sobieszczyk, M. E., & Markowitz, M. (2018). Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1. Expert Opinion on Investigational Drugs, 27(4), 413–420. https://doi.org/10.1080/13543784.2018.1460357

Overton, E. T., Richmond, G., Rizzardini, G., Jaeger, H., Orrell, C., Nagimova, F., Bredeek, F., García Deltoro, M., Swindells, S., Andrade-Villanueva, J. F., Wong, A., Khuong-Josses, M.-A., Van Solingen-Ristea, R., van Eygen, V., Crauwels, H., Ford, S., Talarico, C., Benn, P., Wang, Y., … Spreen, W. (2020). Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. The Lancet, 396(10267), 1994–2005. https://doi.org/10.1016/S0140-6736(20)32666-0

Ramöller, I. K., Abbate, M. T. A., Vora, L. K., Hutton, A. R. J., Peng, K., Volpe-Zanutto, F., Tekko, I. A., Moffatt, K., Paredes, A. J., McCarthy, H. O., & Donnelly, R. F. (2022). HPLC-MS method for simultaneous quantification of the antiretroviral agents rilpivirine and cabotegravir in rat plasma and tissues. Journal of Pharmaceutical and Biomedical Analysis, 213, 114698. https://doi.org/10.1016/j.jpba.2022.114698

Singh, S., & Bakshi, M. (2000). Guidance on the conduct of stress tests to determine inherent stability of drugs. Pharmaceutical Technology Asia, 24.

Vejendla, A., Talari, S., Moturu, R., Boddapati, S. N. M., & Kola, A. E. (2021). Method development and validation for Cabotegravir and Rilpivirine by using HPLC and its degradants are characterized by LCMS and FTIR. Future Journal of Pharmaceutical Sciences, 7(1), 226. https://doi.org/10.1186/s43094-021-00355-8

Wang, Y., De Clercq, E., & Li, G. (2019). Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment. Expert Opinion on Drug Metabolism & Toxicology, 15(10), 813–829. https://doi.org/10.1080/17425255.2019.1673367